Literature DB >> 27725896

Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression.

Chao-Qun Wang1, Hao-Ting Sun1, Xiao-Mei Gao2, Ning Ren3, Yuan-Yuan Sheng2, Zheng Wang1, Yan Zheng2, Jin-Wang Wei2, Kai-Li Zhang2, Xin-Xin Yu2, Yin Zhu1, Qin Luo2, Lu-Yu Yang1, Qiong-Zhu Dong4, Lun-Xiu Qin4.   

Abstract

Interleukin-6 (IL-6), one of the most important inflammatory cytokines, plays a pivotal role in metastasis and stemness of solid tumors. However, the underlying mechanisms of IL-6 in HCC metastasis remain unclear. In the present study, we demonstrated that stemness and metastatic potential of HCC cells were significantly enhanced after IL-6 stimulation. IL-6 could induce expression of osteopontin (OPN), along with other stemness-related genes, including HIF1α, BMI1, and HEY1. Block of OPN induction could significantly abrogate the effect of IL-6 on stemness and metastasis of HCC cells. Furthermore, IL-6 level was positively correlated with OPN in HCC. Patients with high plasma IL-6 or OPN level had poorer prognosis. In multivariate analysis, IL-6 and OPN were demonstrated to be independent prognostic indicators for HCC patients, and their combination had a better prognostic performance than IL-6 or OPN alone. Collectively, our findings indicate that IL-6 could enhance stemness and promote metastasis of HCC via up-regulating OPN expression, which can be a potential therapeutic target for combating HCC metastasis, and the combination of IL-6 and OPN serves as a promising prognostic predictor for HCC.

Entities:  

Keywords:  Liver cancer; cancer stem cell; inflammatory factor; prognosis

Year:  2016        PMID: 27725896      PMCID: PMC5043100     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  35 in total

1.  Randomized Phase II Study of the Anti-inflammatory Effect of Ghrelin During the Postoperative Period of Esophagectomy.

Authors:  Akihiro Takata; Shuji Takiguchi; Yasuhiro Miyazaki; Hiroshi Miyata; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Masaki Mori; Kenji Kangawa; Yuichiro Doki
Journal:  Ann Surg       Date:  2015-08       Impact factor: 12.969

2.  Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.

Authors:  Y Li; Z Y Tang; S L Ye; Y K Liu; J Chen; Q Xue; J Chen; D M Gao; W H Bao
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model.

Authors:  Syamal D Bhattacharya; Zhiyong Mi; Victoria M Kim; Hongtao Guo; Lindsay J Talbot; Paul C Kuo
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

4.  Hepatic stellate cells activated by acidic tumor microenvironment promote the metastasis of hepatocellular carcinoma via osteopontin.

Authors:  Jin Song; Zhouhong Ge; Xinrong Yang; Qin Luo; Cun Wang; Haiyan You; Tianxiang Ge; Yun Deng; Hechun Lin; Yongqi Cui; Wei Chu; Ming Yao; Zhigang Zhang; Jianren Gu; Jia Fan; Wenxin Qin
Journal:  Cancer Lett       Date:  2014-10-27       Impact factor: 8.679

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma.

Authors:  Jian Sun; Hong-Mei Xu; Hai-Jun Zhou; Qiong-Zhu Dong; Yue Zhao; Li-Yun Fu; Zhen-Yu Hei; Qing-Hai Ye; Ning Ren; Hu-Liang Jia; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

7.  Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma.

Authors:  Qiong-Zhu Dong; Xiao-Fei Zhang; Yue Zhao; Hu-Liang Jia; Hai-Jun Zhou; Chun Dai; Hai-Jing Sun; Yi Qin; Wei-De Zhang; Ning Ren; Qing-Hai Ye; Lun-Xiu Qin
Journal:  Hepatology       Date:  2013-02-11       Impact factor: 17.425

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  Regulation of cancer stem cell activities by tumor-associated macrophages.

Authors:  Masahisa Jinushi; Muhammad Baghdadi; Shigeki Chiba; Hironori Yoshiyama
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

10.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

Authors:  Tracy L Putoczki; Stefan Thiem; Andrea Loving; Rita A Busuttil; Nicholas J Wilson; Paul K Ziegler; Paul M Nguyen; Adele Preaudet; Ryan Farid; Kirsten M Edwards; Yeliz Boglev; Rodney B Luwor; Andrew Jarnicki; David Horst; Alex Boussioutas; Joan K Heath; Oliver M Sieber; Irina Pleines; Benjamin T Kile; Andrew Nash; Florian R Greten; Brent S McKenzie; Matthias Ernst
Journal:  Cancer Cell       Date:  2013-08-12       Impact factor: 31.743

View more
  20 in total

1.  Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling.

Authors:  Yawen Li; Ronghua Wang; Si Xiong; Xiju Wang; Zhenxiong Zhao; Shuya Bai; Yun Wang; Yuchong Zhao; Bin Cheng
Journal:  J Mol Med (Berl)       Date:  2018-12-18       Impact factor: 4.599

2.  Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling.

Authors:  Si Xiong; Ronghua Wang; Qian Chen; Jing Luo; Jinlin Wang; Zhenxiong Zhao; Yawen Li; Yun Wang; Xiju Wang; Bin Cheng
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

3.  Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation.

Authors:  Y Li; M Zhao; C Guo; H Chu; W Li; X Chen; X Wang; Y Li; Y Jia; S Koussatidjoa; F Zhu; J Wang; X Wang; Q Wang; W Zhao; Y Shi; W Chen; L Zhang
Journal:  Oncogene       Date:  2017-11-06       Impact factor: 9.867

Review 4.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

5.  Physical Activity and Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Kara DiJoseph; Audrey Thorp; Alex Harrington; Kathryn H Schmitz; Vernon M Chinchilli; Jonathan G Stine
Journal:  Dig Dis Sci       Date:  2022-06-29       Impact factor: 3.199

Review 6.  Neutrophils as potential therapeutic targets in hepatocellular carcinoma.

Authors:  Daniel Geh; Jack Leslie; Rob Rumney; Helen L Reeves; Thomas G Bird; Derek A Mann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-12       Impact factor: 46.802

Review 7.  IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.

Authors:  Nese Unver; Florencia McAllister
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-18       Impact factor: 7.638

8.  ZEB2 promotes tumor metastasis and correlates with poor prognosis of human colorectal cancer.

Authors:  Ming-Zhe Li; Jing-Jing Wang; Shi-Bin Yang; Wen-Feng Li; Long-Bin Xiao; Yu-Long He; Xin-Ming Song
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

9.  Interleukin-6 as a biomarker in patients with hepatobiliary cancers.

Authors:  Rohit Gosain; Sidra Anwar; Austin Miller; Renuka Iyer; Sarbajit Mukherjee
Journal:  J Gastrointest Oncol       Date:  2019-06

10.  Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.

Authors:  Haoting Sun; Chaoqun Wang; Beiyuan Hu; Xiaomei Gao; Tiantian Zou; Qin Luo; Mo Chen; Yan Fu; Yuanyuan Sheng; Kaili Zhang; Yan Zheng; Xudong Ren; Shican Yan; Yan Geng; Luyu Yang; Qiongzhu Dong; Lunxiu Qin
Journal:  Signal Transduct Target Ther       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.